InBioGen Co Stock

InBioGen Co Equity

The The Equity of InBioGen Co (101140.KS) as of Sep 5, 2026 is 159.84 B KRW. In the previous year, The Equity was 143.08 B KRW — a change of 11.71% (higher).

Equity

159.84 BKRW

YoY

11.71%

Last updated:

In 2026, InBioGen Co's equity was 159.84 B KRW, a 11.71% increase from the 143.08 B KRW equity in the previous year.

The InBioGen Co Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2017
11.32 B KRW
Jan 1, 2018
23.35 B KRW
Jan 1, 2019
66.00 B KRW
Jan 1, 2020
77.91 B KRW
Jan 1, 2021
178.02 B KRW
Jan 1, 2022
106.88 B KRW
Jan 1, 2023
143.08 B KRW
Jan 1, 2024
159.84 B KRW
The InBioGen Co Equity history
YEAREquityYoY
159.84 BKRW+11.71%
143.08 BKRW+33.87%
106.88 BKRW-39.96%
178.02 BKRW+128.51%
77.91 BKRW+18.05%
66.00 BKRW+182.61%
23.35 BKRW+106.22%
11.32 BKRW+96.90%
5.75 BKRW-26.27%
7.80 BKRW+89.14%
4.12 BKRW—
Access this data via the Eulerpool API
Get Free API Key

InBioGen Co Stock analysis

What does InBioGen Co do? InBioGen Co is one of the most popular companies on Eulerpool.

Equity Details

Analyzing InBioGen Co's Equity

InBioGen Co's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding InBioGen Co's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating InBioGen Co's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

InBioGen Co's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in InBioGen Co’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about InBioGen Co stock

The Equity of InBioGen Co is 159.84 B KRW in 2026.

The Equity of InBioGen Co changed from 143.08 B KRW to 159.84 B KRW, representing a 11.71% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity InBioGen Co since 2006 – with annual values, charts, and detailed analysis.

The Equity's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's InBioGen Co historically and in real time.

Access this data via the Eulerpool API
Get Free API Key

Balance Sheet — InBioGen Co

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — InBioGen Co